1
|
Schoemans HM, Goris K, Fieuws S, Theunissen K, Buve K, Lammertijn L, Bries G, Demuynck H, Maertens V, Maes H, Meers S, Schuermans C, Vrelust I, Hodossy B, Huysmans G, Zachee P, Beckers M, Vergote V, Maertens JA, De Geest S, Dobbels F. Life 2.0: A Comprehensive Cross-Sectional Profiling of the ‘New Normal’ in 244 Long-Term Allogeneic Hematopoietic Cell Transplantation Survivors Compared to the General Population. Biol Blood Marrow Transplant 2020. [DOI: 10.1016/j.bbmt.2019.12.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
2
|
Al-Ahmad S, Maertens V, Libeer C, Schelfhout V, Vanhoenacker F, Boeckx N, Vandevenne M. The masquerading presentation of a systemic anaplastic large cell lymphoma, ALK positive: a case report and review of the literature. Acta Clin Belg 2017; 72:454-460. [PMID: 28441913 DOI: 10.1080/17843286.2017.1312057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
We report an unusual case of systemic anaplastic large cell lymphoma (ALCL), ALK positive with leukemic involvement in a 57-year-old woman. The patient presented with a fulminant respiratory infection unresponsive to treatment requiring intensive care and ventilatory support. The CT scan demonstrated mediastinal and bilateral lymphadenopathy. On peripheral smear a few atypical lymphocytes were visualized. Based on the increasing number of atypical lymphocytes in the daily peripheral bloodsmears, the diagnosis ALCL was suggested. Definitive diagnosis was made on a bone marrow biopsy, with lymphocytes being immunoreactive for CD30, EMA, and ALK. Leukemic peripheral blood involvement in ALCL is an uncommon clinicopathologic entity with unfavorable prognosis. The case we present is perhaps unusual in that a complete respons was achieved, highlighting the importance of prompt diagnosis and judicious management.
Collapse
Affiliation(s)
| | - Vincent Maertens
- Department of Hematology, AZ Sint Maarten, Mechelen-Duffel, Belgium
| | | | - Vera Schelfhout
- Department of Pathology, AZ Sint Maarten, Mechelen-Duffel, Belgium
| | | | - Nancy Boeckx
- Department of Laboratory Medicine, UZ Leuven, Leuven, Belgium
| | - Marleen Vandevenne
- Department of Laboratory Medicine, AZ Sint Maarten, Mechelen-Duffel, Belgium
| |
Collapse
|
3
|
Vergote V, Janssens A, André M, Bonnet C, Van Hende V, Van Den Neste E, Van Eygen K, Maerevoet M, Pranger D, Schroyens W, Debussche S, Maertens V, Beel K, Lemmens J, Caron C, Delrieu V, Van Den Broeck I, Vanstraelen G, Jacquy C, Schauvlieghe L, De Samblanx H, Madoe V, Meers S, Boulet D, Verhoef G, Van Hoof A. Results from the Belgian mantle cell lymphoma registry. Acta Clin Belg 2017; 72:172-178. [PMID: 28222652 DOI: 10.1080/17843286.2017.1293328] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Mantle cell lymphoma is a B-cell non-Hodgkin's lymphoma characterized by a t(11;14), resulting in overexpression of cyclin D1. Conventional chemotherapy obtains frequent (but short) remissions, leading to a poor median overall survival (OS) of 3-5 years. To obtain more information about the prevalence and current treatment of Mantle cell lymphoma (MCL) in Belgium, we collected data in a Belgian registry of MCL. MATERIALS AND METHODS All Belgian MCL patients, t(11;14) and/or cyclin D1 positive, seen in hematology departments over a one-year period (April 2013-March 2014) were included. Data about patient characteristics, histology, treatment lines, and response were compiled and retrospectively analyzed. RESULTS Four hundred and four patients were included with a median age at diagnosis of 64 years (range 23-96 years) and a male predominance (72%). For 2013, we calculated a prevalence of at least 36.2 per million and an incidence of at least 7.0 per million in the Belgian population. Characteristics at diagnosis involved lymphadenopathy (82%), splenomegaly (44%), B-symptoms (39%), and hepatomegaly (10%). Bone marrow invasion was present at diagnosis in 77%. Stage at diagnosis was advanced in the majority of cases. The median number of treatment lines was 1. Type of first line treatment included a combination of anthracyclin and cytarabine-based regimen (34%), anthracyclin (39%), and other. Rituximab was used in 88% of first line treatments. In 44% first line treatment was followed by autologous stem cell transplantation. CONCLUSION The analysis of this Belgian MCL registry provides insight in the epidemiology, demographics, and current treatment of our Belgian MCL population.
Collapse
Affiliation(s)
| | - Ann Janssens
- Department of Hematology, UZ Leuven, Leuven, Belgium
| | - Marc André
- Department of Hematology, CHU UCL Namur, Yvoir, Belgium
| | | | | | - Eric Van Den Neste
- Department of Hematology, Cliniques universitaires Saint Luc, Brussels, Belgium
| | - Koen Van Eygen
- Department of Hematology, AZ Groeninge, Kortrijk, Belgium
| | - Marie Maerevoet
- Department of Hematology, Institut Jules Bordet, Brussels, Belgium
| | | | | | | | | | - Karolien Beel
- Department of Hematology, ZNA Middelheim, Antwerpen, Belgium
| | - Jan Lemmens
- Department of Hematology, GZA St. Augustinus, Antwerpen, Belgium
| | | | - Vanessa Delrieu
- Department of Hematology, Hôpital de Jolimont, La Louvière, Belgium
| | | | | | - Caroline Jacquy
- Department of Hematology, CHR de la Citadelle, Liège, Belgium
| | | | | | | | - Stef Meers
- Department of Hematology, AZ KLINA, Antwerpen, Belgium
| | | | | | | |
Collapse
|